DURATA THERAPT (DRTX) Downgraded by Zacks to NEUTRAL

Zacks Zacks Investment Research downgraded shares of DURATA THERAPT (DRTX) from OUTPERFORM to NEUTRAL on November 05, 2014, with a target price of $29.10.

Durata Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of therapeutics for patients with infectious diseases and acute illnesses. The Company is developing dalbavancin, an intravenous antibiotic product candidate, for the treatment of patients with acute bacterial skin and skin structure infections. Durata Therapeutics, Inc. is headquartered in Morristown, New Jersey.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

To get a free copy of the research report on DURATA THERAPT (DRTX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .

Be the first to comment

Leave a Reply